Get the Stockscreener App
1.33
5.00%
-0.07
After Hours:
1.33
In 8 Bio Inc stock is traded at $1.33, with a volume of 113.18K.
It is down -5.00% in the last 24 hours and down -5.00% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.40
Open:
$1.44
24h Volume:
113.18K
Relative Volume:
1.96
Market Cap:
$12.75M
Revenue:
-
Net Income/Loss:
$-18.98M
P/E Ratio:
-0.4661
EPS:
-2.8535
Net Cash Flow:
$-14.55M
1W Performance:
-6.34%
1M Performance:
-5.00%
6M Performance:
-43.40%
1Y Performance:
-41.92%
1-Day Range:
$1.31
$1.44
1-Week Range:
$1.28
$1.46
52-Week Range:
$1.17
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.33 | 13.43M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma - GlobeNewswire Inc.
Form 4 Boundless Bio Inc For: 8 July By Investing.com - Investing.com Canada
Ten percent owner of Boundless Bio (NASDAQ: BOLD) adds shares - Stock Titan
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Morningstar
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price - Stock Titan
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
Avai Bio (AVAI) notifies SEC of late FY2026 10-K, cites financial compilation - Stock Titan
Tang-linked entities report 11.3% stake in Boundless Bio (NASDAQ: BOLD) - Stock Titan
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan
[144] Nuvation Bio Inc. SEC Filing - Stock Titan
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
LeonaBio (NASDAQ: LONA) shareholders approve directors, EY auditor and executive pay cadence - Stock Titan
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Serapha Bio to take control of Boundless Bio (NASDAQ: BOLD) in cash-dividend merger - Stock Titan
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
Valion Bio (VBIO) CFO exercises 92 RSUs, holds 618 common shares after conversion - Stock Titan
Adicet Bio (ACET) investors back board nominees, pay and KPMG at 2026 meeting - Stock Titan
Valion Bio (NASDAQ: VBIO) adds $250,000 via Series B preferred share and warrant sale - Stock Titan
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
Boundless Bio, Inc. Files 8-K with SEC: Company Details, Stock Info, and Emerging Growth Status Revealed - Minichart
[8-K] Boundless Bio, Inc. Reports Material Event - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Kyntra Bio, Inc. 8-K SEC Filing Details June 12, 2026 – Company Information, Address, and Stock Listing - Minichart
[Form 4] Boundless Bio, Inc. Insider Trading Activity - Stock Titan
Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor - Stock Titan
BioRestorative Therapies (NASDAQ: BRTX) adds $1M revolver and installs lender-backed directors - Stock Titan
Instil Bio (TIL) director Gwendolyn Binder awarded 6,500 stock options at $7.93 - Stock Titan
KALA BIO (NASDAQ: KALA) registers $350M shelf; 1-for-50 reverse split recorded - Stock Titan
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
TELA Bio (NASDAQ: TELA) OKs 3.5M-share incentive plan boost - Stock Titan
Climb Bio reports encouraging Phase 1b ITP data; 250 mg cohort shows durable platelet gains - TradingView
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
683 Capital reports 49.87M-share position in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):